title: Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.
abstract: Ra-223 (radium-223) is an alpha particle-emitting radiopharmaceutical with targeted uptake in areas of osteoblastic lesions. The combination of targeted skeletal uptake, short tissue-penetration range, and high energy of alpha particles allows for targeted cell killing and a low toxicity profile. A phase III trial (ALSYMPCA) demonstrated improvements in overall survival and symptomatic skeletal events in patients with castration-resistant prostate cancer and multifocal symptomatic bone metastases. Adverse events were limited but included both gastrointestinal and hematologic effects. This article will describe the historic background of Ra-223; outline the clinical studies which led to phase III trials of this agent; highlight key results of these phase III studies; and explore possible future directions for use of Ra-223 and other alpha particles--both in prostate cancer and for management of other diseases.
authors.forename: Brian
authors.initials: B
authors.lastname: Lewis
authors.forename: Elie
authors.initials: E
authors.lastname: Chalhoub
authors.forename: Carla
authors.initials: C
authors.lastname: Chalouhy
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011883:Radium / Q000627:therapeutic use*
chemical_list: D000469:Alkaline Phosphatase; D011883:Radium